. Author manuscript; available in PMC: 2014 Jun 1.

Published in final edited form as: Invest New Drugs. 2012 Nov 15;31(3):769–773. doi: 10.1007/s10637-012-9897-4

Table 1.

Baseline Patient Characteristics

	Number	Percent (%)
Median Age	63
Range	25–80
ECOG Performance Status
0	13	57
1	10	43
Sex
Male	15	65
Female	8	35
Mean Baseline LDH (U/L)	238
Range	123–573
Prior Therapy for Advanced Melanoma	18	78
Immunotherapy	9^*	39
Chemotherapy	9^**	39
Prior Adjuvant Interferon alpha	6	26

Includes 1 patient treated with combination immune- and chemotherapy

^**

Includes 2 patients treated on a trial of dacarbazine with either ipilimumab or placebo